ClinicalTrials.gg
TerminatedNCT06015659Updated Oct 27, 2026Results posted

ZN-c3 + Gemcitabine in Pancreatic Cancer

A Phase 2 interventional study of Zentalis and Gemzar in Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Brandon Huffman, MD. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Brandon Huffman, MD · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.
Updated Oct 27, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
1,251st of 1,573
12 · median 37
Started
2023
with 76 others
Phase 2
488 of 1,850
45 open now
Registered
1,610th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 1,251st largest by enrollment of the 1,573 interventional ones that give a count, is one of 77 that started in 2023, is one of 488 in phase 2, and was the 1,610th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer.

The names of the study drugs involved in this study are:

  • ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)
  • Gemcitabine (a nucleoside metabolic inhibitor)
Read the detailed description

This is an open label, single arm phase 2 trial evaluating ZN-c3 combined with gemcitabine in second-line advanced pancreatic cancer. There are lab experiments that show that pancreatic cancer cells can respond to a combination of ZN-c3, an experimental drug, with gemcitabine.

The U.S. Food and Drug Administration (FDA) has not approved ZN-c3 as a treatment for any disease. The FDA has approved gemcitabine as a treatment option for advanced pancreatic cancer.

The research study procedures include screening for eligibility, study treatment including evaluations and follow up visits, radiological scans (Computerized Tomography, Magnetic Resonance Imaging, or Positron Emission Tomography), blood tests, electrocardiogram, and tumor biopsy.

It is expected that about 34 people will take part in this research study.

The Lustgarten Foundation for Pancreatic Research and Stand Up to Cancer are supporting this research study by providing funding to conduct the study. Zentalis is supplying the study drug, ZN-c3.

03

Conditions studied

  • Advanced Pancreatic Adenocarcinoma
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Advanced Pancreatic Adenocarcinoma
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed advanced pancreatic adenocarcinoma that is not curable with standard approaches based on the judgement of the treating investigator. Patients with pancreatic cancer and unresectable pancreatic cancer are eligible.
  • Patients must have progressed or not tolerated a platinum-based regimen prior to enrolling on the trial.
  • Patients must have received no more than 1 prior lines of platinum-based chemotherapy in the metastatic setting. Therapy given in the or neoadjuvant setting is counted as a prior therapy if it occurred less than 6 months before cancer recurrence or progression.
  • Age ≥ 18 years. As no dosing or adverse event data are currently available in participants \< 18 years of age, children and adolescents are excluded from this study.
  • performance status of 0 or 1 (see Appendix A) with no deterioration over the previous 2 weeks prior to day of first dosing (Cycle 1, Day 1).
  • Participants must have adequate organ and marrow function as defined below:

    • ≥ 1,500/mm3
    • ≥ 100,000/mm3 excluding measurements obtained within 3 days after transfusion of platelets
    • ≥ 9 g/dL
    • Total ≤ 1.5 × institutional (ULN); or total bilirubin ≤3.0 x ULN with direct bilirubin WNL in patients with documented Gilbert's Syndrome.
    • (ALT) and aspartate aminotransferase (AST) Albumin ≤2.5 x institutional ULN; ≤ 5 × institutional ULN if liver metastases ≥ 2.7 g/dL
    • (CrCl) ≥ 50 ml/min based on Cockroft-Gault method
  • Participants must have by v. 1.1 criteria and be willing to undergo a pre-treatment and on-treatment tumor . The biopsy requirement can be waived only with approval from the sponsor-investigator.
  • For participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated, unless there is a drug-drug interaction with study medication.
  • Patient has read and understands the form (ICF) and has been given written ICF prior to any study procedures which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Female patients who are not of * and women of childbearing potential who agree to use adequate measures prior to the first dose and for 90 days after the last dose of ZN-c3, and who have a negative serum or urine pregnancy test within 14 days prior to the start of study treatment.

    --Evidence of non-childbearing status, defined as below:

    • Women who are surgically sterile (i.e., have undergone bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy).
    • Age ≥50 years with any one or more of the conditions below:

      • Amenorrheic for 12 months or more following cessation of all hormonal replacement therapy
      • Had radiation-induced menopause with last menses >1 year ago
      • Had chemotherapy-induced menopause with last menses >1 year ago
    • Age \<50 if amenorrhoeic for 12 months or more following cessation of all hormonal replacement therapy and if luteinizing hormone and follicle- stimulating hormone levels are in the range per institutional standards of practice.
  • Male patients should be willing to abstain or use barrier contraception (i.e., condoms) for the duration of the study drug exposure and for 90 days after the last dose of ZN- c3 after study treatment discontinuation.
  • Participants with a history of virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load, unless there is a drug-drug interaction with study medication.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received a WEE1 inhibitor are not eligible.
  • Patients who received gemcitabine for incurable pancreatic cancer (locally advanced unresectable or ) or patients progressing within 6 months of receiving /adjuvant gemcitabine.
  • Use of an anti-cancer treatment drug ≤ 21 days or 5 half-lives (whichever is shorter) prior to the first dose of ZN-c3.
  • Active use of treatment prescription or non-prescription drugs, or food and herbal supplements, that are strong/moderate inhibitors, P-gp inhibitors, or strong CYP3A4 inducers.
  • Any prior palliative radiation to ≥5% of the bone marrow, and must have been completed and recovered from adverse effects of therapy at least 21 days prior to the first dose of ZN-c3.
  • Participants who have undergone major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, of the first dose of ZN-c3. No waiting period is required following port-a-cath or other central venous access placement.
  • Presence of v5.0 Grade >1 toxicity from prior therapy (except alopecia, anorexia or CTCAE grade 2 peripheral neuropathy).
  • Patient is unable to swallow oral medications. Note: Patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN).
  • Participants with known malignant central nervous system (CNS) disease other than neurologically stable, treated - defined as metastasis having no evidence of progression or hemorrhage for at least 2 weeks after the completion of treatment (including brain radiotherapy). Must be off any systemic for the treatment of brain metastases for at least 14 days prior to enrollment.
  • History of to compounds of similar chemical or biologic composition to gemcitabine or ZN-c3.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection*, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Recurrent, active or suspected infection and/or patients who are predisposed to an increased risk of severe infection. Patients with infections that require antibiotics or antifungal agents may be eligible, provided that infection is resolved and treatment is completed at least 7 days prior to study treatment start.
  • Participants with a gastrointestinal disorder that in the opinion of the treating investigator could impact the absorption of the study drugs, including but not limited to nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of ZN-c3.
  • Participants with a history of a clinically relevant second primary within the past 2 years. Exceptions include: resected basal and squamous cell carcinomas of the skin and completely resected carcinoma in situ of any type.
  • Administration of strong or moderate CYP3A4 inhibitors or inducers and P-gp inhibitors. (See Appendix B)
  • Pregnant or lactating women are excluded from this study because gemcitabine/ZN- c3 are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with gemcitabine/ZN-c3, breastfeeding should be discontinued if the mother is treated with gemcitabine/ZN-c3.
  • Any of the following cardiac diseases currently or within 6 months of the first dose of ZN-c3:

    • 12-lead demonstrating a interval using Fridericia's formula (QTcF) of >470 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    ZN-c3 + Gemcitabine

    Study procedures will be conducted as follows: * Cycle 1 - End of Treatment * Days 1 - 5 of 21-day cycle: Predetermined dose of ZN-c3 1x daily. * Days 8 - 12 of 21-day cycle: Predetermined dose of ZN-c3 1x daily. * Days 15 - 19 of 21-day cycle: Predetermined dose of ZN-c3 1x daily. * Day 1 and 8 of 21-day cycle: Predetermined dose of Gemcitabine 1x daily. * On-treatment tumor biopsy will be collected on either Cycle 1 Day 9 - 10 or Cycle 2 Day 9 - 10. * Tumor assessment by Computerized Tomography (CT) or Magnetic Resonance Imaging scan every 8 weeks while on treatment. * End of treatment visit with tumor assessment by CT or MRI and optional tumor biopsy. * Follow up visit every 2 months after treatment has ended.

    Drug: Zentalis · Drug: Gemzar

Interventions

  • DrugZentalis

    Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.

    Also known as: Zn-c3, KP-2638, azenosertib, C29H34N8O2.

  • DrugGemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nucleoside metabolic inhibitor, per standard care via intravenous infusion.

    Also known as: Gemcitabine hydrochloride, FF 10832, LY188011, C9H11F2N3O4 - HCl

06

What researchers measure

Primary outcomes

  1. 6-month Progression-Free Survival (PFS) Rate

    6-month PFS rate is the percentage of participants remaining alive and progression free at 6 months. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.

    Time frame: 6 months

Secondary outcomes

  1. Median Overall Survival (OS)

    Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.

    Time frame: 18 months

  2. Median Progression-Free Survival (PFS)

    Progression-free survival based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) or death, or is censored at time of last disease assessment.

    Time frame: 18 months

  3. Objective Response Rate (ORR)

    The objective response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECISTv1.1 criteria.

    Time frame: 18 months

  4. Grade 3-5 Treatment-related Toxicity Rate

    All grade 3-5 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 that are not resolved in accordance with treatment guidelines were counted. Rate is the proportion of treated participants experiencing at least one of these adverse events as defined during the time of observation.

    Time frame: 18 months

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneDose Level -1Dose Level 1
Started57
Completed57
Not completed00

Outcome measures

Primary6-month Progression-Free Survival (PFS) Rate

6-month PFS rate is the percentage of participants remaining alive and progression free at 6 months. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.

Time frame:
6 months
Reported as:
Number · percent of participants
6-month Progression-Free Survival (PFS) Rate
percent of participantsAll Study Participants
6-month Progression-Free Survival (PFS) Rate16.7 (4.7 to 59.1)
SecondaryMedian Overall Survival (OS)

Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.

Time frame:
18 months

Results for this outcome have not been posted.

SecondaryMedian Progression-Free Survival (PFS)

Progression-free survival based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) or death, or is censored at time of last disease assessment.

Time frame:
18 months

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR)

The objective response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECISTv1.1 criteria.

Time frame:
18 months

Results for this outcome have not been posted.

SecondaryGrade 3-5 Treatment-related Toxicity Rate

All grade 3-5 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 that are not resolved in accordance with treatment guidelines were counted. Rate is the proportion of treated participants experiencing at least one of these adverse events as defined during the time of observation.

Time frame:
18 months

Results for this outcome have not been posted.

Adverse events

Collected over 18 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level -15/5 (100%)3/5 (60%)5/5 (100%)
Dose Level 17/7 (100%)5/7 (71.4%)7/7 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventDose Level -1Dose Level 1
Thromboembolic eventVascular disorders1/52/7
Abdominal painGastrointestinal disorders1/51/7
Gastrointestinal disorders - Other, specify: GI bleedGastrointestinal disorders1/50/7
Lung infectionInfections and infestations1/51/7
Hip fractureInjury, poisoning and procedural complications1/50/7
Hepatobiliary disorders - Other, specify: biliary obstructionHepatobiliary disorders0/51/7
Skin infectionInfections and infestations0/51/7
Platelet count decreasedInvestigations0/51/7
HyperglycemiaMetabolism and nutrition disorders0/51/7
Back painMusculoskeletal and connective tissue disorders0/51/7
Most frequent other events
Showing 10 of 70
Most frequent other events
EventDose Level -1Dose Level 1
Alanine aminotransferase increasedInvestigations5/54/7
Platelet count decreasedInvestigations5/55/7
HypoalbuminemiaMetabolism and nutrition disorders5/54/7
AnemiaBlood and lymphatic system disorders4/55/7
Aspartate aminotransferase increasedInvestigations4/53/7
Abdominal painGastrointestinal disorders2/55/7
DiarrheaGastrointestinal disorders1/55/7
HyponatremiaMetabolism and nutrition disorders2/55/7
ConstipationGastrointestinal disorders3/51/7
Edema limbsGeneral disorders2/54/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dose Level -1Dose Level 1Total
<=18 years000
Between 18 and 65 years347
>=65 years235
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level -1Dose Level 1Total
Female369
Male213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level -1Dose Level 1Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American011
White358
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)Dose Level -1Dose Level 1Total
United States5712
08

Study locations

1 site
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2023 to primary completion in Aug 2025, 20 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → May 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Aug 29, 2023
StartActual
Nov 16, 2023
Primary completionActual
Aug 6, 2025
CompletionActual
May 23, 2026was Jun 2027
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.
changed Oct 27, 2026
Results
Results posted
posted Oct 27, 2026
Study completion
Jun 1, 2027→May 23, 2026 (actual)
Oct 27, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frame6-month Progression-Free Survival (PFS) Rate18 months → 6 months
  • Description6-month Progression-Free Survival (PFS) Rate: how it is measured was reworded
Oct 27, 2026
Documents
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Terminated
    Why stopped Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.
    Results posted
    Study completion Jun 1, 2027→May 23, 2026 (now actual)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frame6-month Progression-Free Survival (PFS) Rate18 months → 6 months
    • Description6-month Progression-Free Survival (PFS) Rate: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06015659
Lead sponsor
Brandon Huffman, MD
Collaborators
Lustgarten Foundation, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Stand Up To Cancer
Responsible party
Brandon Huffman, MD (Sponsor Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Aug 29, 2023
Start date
Nov 16, 2023
Primary completion
Aug 6, 2025
Completion
May 23, 2026
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Brandon Huffman, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion